Dimitrios Makrakis

Dr. Dimitrios Makrakis

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
Dimitra Rafailia BakaloudiDimitra Rafailia Bakaloudi
Dimitra Rafailia Bakaloudi
RTRafee Talukder
Rafee Talukder
GLGenevieve Ihsiu Lin
Genevieve Ihsiu Lin
DMDimitrios Makrakis
Dimitrios Makrakis
LDLeonidas N. Diamantopoulos
Leonidas N. Diamantopoulos
PGPetros Grivas
Petros Grivas

5 June 2022 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
DMDimitrios Makrakis
Dimitrios Makrakis
RTRafee Talukder
Rafee Talukder
GLGenevieve Ihsiu Lin
Genevieve Ihsiu Lin
LDLeonidas N. Diamantopoulos
Leonidas N. Diamantopoulos
SDScott Dawsey
Scott Dawsey
AKAli Raza Khaki
Ali Raza Khaki

10 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Marcus SkribekMarcus Skribek
Marcus Skribek
KRKonstantinos Rounis
Konstantinos Rounis
DMDimitrios Makrakis
Dimitrios Makrakis
Sofia AgelakiSofia Agelaki
Sofia Agelaki
Dimitrios MavrudisDimitrios Mavrudis
Dimitrios Mavrudis
GTGeorgios Tsakonas
Georgios Tsakonas
There is lack of data addressing the intracranial (IC) efficacy of immune checkpoint inhibitors (ICIs) on brain metastases (BM) in non-small cell lung cancer (NSCLC). This patient category is underrepresented in randomized clinical trials. We retrospectively collected clinical data on patients with non-oncogenic driven NSCLC with BM who were treated with ICIs at two medical oncology institutes in Sweden and Greece from 2016 to 2019. IC efficacy was assessed in patients who had not received local treatment for BM less than three months prior to the initiation of ICIs and had adequate radiological evaluation. We screened 280 patients, of which 51 had BM. BM was an independent predictor for inferior PFS (HR = 2.27; 95% CI, 1.53–3.36) but not OS (HR = 1.58; 95% CI, 0.97–2.60) for the whole patient population. IC response assessment was done on 33 patients. IC objective response rate (ORR) was 24.2%. The presence of neurological symptoms related to BM did not affect IC ORR (p = 0.48). High PD-L1 levels from extracranial biopsies were not a predictive factor for IC ORR (p = 0.13). ICIs are active in NSCLC patients with BM regardless of the presence of neurological symptoms and can achieve durable IC disease stabilization in a subgroup of patients.

19 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
CPCHARA PAPADAKI
CHARA PAPADAKI
AMAlexia Monastirioti
Alexia Monastirioti
KRKonstantinos Rounis
Konstantinos Rounis
DMDimitrios Makrakis
Dimitrios Makrakis
KKKonstantinos Kalbakis
Konstantinos Kalbakis
Sofia AgelakiSofia Agelaki
Sofia Agelaki
The expression of microRNA (miR)-21, miR-128, miR-155, and miR-181a involved in DNA damage response (DDR) and tumor responsiveness to platinum was assessed by RT-qPCR in the plasma of patients with non-small cell lung cancer (NSCLC; n = 128) obtained prior to initiation of first-line platinum chemotherapy. U6 small nuclear RNA (snRNA) was used for normalization, and fold change of each miRNA expression relative to the expression in healthy controls was calculated by the 2−ΔΔCt method. MicroRNA expression levels were correlated with patients’ outcomes. Integrated function and pathway enrichment analysis was performed to identify putative target genes. MiR-128, miR-155, and miR-181a expressions were higher in patients compared to healthy donors. MiRNA expression was not associated with response to treatment. High miR-128 and miR-155 were correlated with shorter overall survival (OS), whereas performance status (PS) 2 and high miR-128 independently predicted for decreased OS. In the squamous (SqCC) subgroup (n = 41), besides miR-128 and miR-155, high miR-21 and miR-181a expressions were also associated with worse survival and high miR-155 independently predicted for shorter OS. No associations of miRNA expression with clinical outcomes were observed in patients with non-SqCC (n = 87). Integrated function and pathway analysis on miRNA targets revealed significant enrichments in hypoxia-related pathways. Our study shows for the first time that plasma miR-128 and miR-155 hold independent prognostic implications in NSCLC patients treated with platinum-based chemotherapy possibly related to their involvement in tumor response to hypoxia. Further studies are needed to investigate the potential functional role of these miRNAs in an effort to exploit their therapeutic potential.

1 December 2011
Verified
Conference Paper
Closed access
BVBinod Vaidya
Binod Vaidya
DMDimitrios Makrakis
Dimitrios Makrakis
Hussein MouftahHussein Mouftah
Hussein Mouftah
Plug-in electric vehicles (PEVs) reduce greenhouse gas emission by using power from the electric grid. PEVs are considered distributed energy resources and mobile storage devices, which require two-way communication standards to communicate with emerging Smart Grid infrastructure. Due to frequent mobility of PEVs, inter-utility real-time data communication is critical to the operation of interconnected systems in Vehicle-to-Grid (V2G) infrastructure. Interoperability and security considerations of V2G infrastructure components are decisive for widespread deployment of PEVs. In this paper, we propose multi-domain network architecture for V2G infrastructure which includes comprehensive hybrid public key infrastructure using hierarchical and peer-to-peer cross-certifications. We present system and performance analysis of the proposed security architecture.

10 February 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DMDimitrios Makrakis
Dimitrios Makrakis
KRKonstantinos Rounis
Konstantinos Rounis
ATAlexandros-Pantelis Tsigkas
Alexandros-Pantelis Tsigkas
AGAlexandra Georgiou
Alexandra Georgiou
NGNikolaos Galanakis
Nikolaos Galanakis
SASofia Agelaki
Sofia Agelaki
Obesity and sarcopenia have been reported to affect outcomes in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). We analyzed prospective data from 52 patients with non-oncogene driven metastatic NSCLC treated with ICIs. Body tissue composition was calculated by measuring the fat and muscle densities at the level of 3rd lumbar vertebra in each patient computed tomography scan before ICI initiation using sliceOmatic tomovision. We converted the densities to indices [Intramuscular Fat Index (IMFI), Visceral Fat Index (VFI), Subcutaneous Fat Index (SFI), Lumbar Skeletal Muscle Index (LSMI)] by dividing them by height in meters squared. Patients were dichotomized based on their baseline IMFI, VFI and SFI according to their gender-specific median value. The cut-offs that were set for LMSI values were 55 cm2/m2 for males and 39 cm2/m2 for females. SFI distribution was significantly higher (p = 0.040) in responders compared to non-responders. None of the other variables affected response rates. Low LSMI HR: 2.90 (95% CI: 1.261–6.667, p = 0.012) and low SFI: 2.20 (95% CI: 1.114–4.333, p = 0.023) values predicted for inferior OS. VFI and IMFI values did not affect survival. Subcutaneous adipose and skeletal muscle tissue composition significantly affected immunotherapy outcomes in our cohort.